Skip to content Skip to menu

Medicines Australia appoints new chairman

Tuesday, 1 May 2012

Media Release

The Board of Medicines Australia today announced the appointment of Mr Mark Masterson as its new chairman.

Mr Masterson was formerly chief executive at I-MED Network, Australia’s largest private diagnostic imaging network. This follows a 20 year career in international and Australian roles in the medicines industry as vice president, Asia Pacific Africa at Abbott and General Manager ANZ at Abbott Laboratories.

Mr Masterson said: “I am very excited to be joining the Medicines Australia Board as Chairman at a time of great opportunity and challenge for the medicines industry.

“This is a genuinely exciting time for the industry in Australia and I am looking forward to working with the board and with our member companies to ensure we can capitalise on some of those opportunities.”

“While the industry is facing many challenges here and internationally, fundamentally this is an industry that deserves greater recognition for the value it brings to society.

“I look forward to representing the industry in Australia as a way to promote the value that it contributes.

Medicines Australia chief executive Dr Brendan Shaw said Mr Masterson’s appointment was extremely positive for the medicines industry.

“Mark’s vast and varied experience in numerous senior roles globally in Australia will be enormously valuable to the board and membership of Medicines Australia,” Dr Shaw said.

“He will be a passionate advocate for the interests of our member companies.”

Mr Masterson succeeds Will Delaat, who retired as independent chairman of Medicines Australia after 14 years on the board and six as chairman.


Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at